Transforming Life Science Enterprises with Agentic AI

Chatbots have been the public face of artificial intelligence for quite some time. They answered questions, routed tickets, summarized content, and made AI feel a bit more accessible. They filled a unique gap at the time, but they can do so much.

When chatbots began dominating the scene, it felt revolutionary; however, we are now entering a second, more consequential phase of AI adoption. One that moves beyond the conversation and dives into coordinated action. Agentic AI’s emergence is not just a system that responds to prompts; it actively plans, executes, adapts, and learns in pursuit of defined goals.

While this shift is taking root across industries, it matters most in areas where complexity, regulation, and high-stakes decisions intersect. Coincidentally, life sciences sit at the crux of that intersection

Let’s look at how.

What Chatbots Did Right — and Where They Hit the Wall

Before we get into the breakdown, let’s take a look at how chatbots function. We must give chatbots their flowers. They helped organizations scale customer support, reduce response times, and automate routine interactions, delivering business value without requiring a complete system rewrite. However, with the structural limitations, they were reactive by design. They waited for prompts, generated responses, and stopped there. They could not plan, and they didn’t own outcomes, and struggled when tasks spanned multiple systems or evolved midstream.

One of the most famous chatbot dead ends, “I didn’t understand this question,” has left far more people frustrated than we have time to count. Chatbots were essentially one of the first waves of AI adoption because they were easy to deploy and understand. A natural rinse and repeat.

What “Agentic AI” Actually Means (Without the Jargon)

Let’s examine agentic AI. 

Agentic AI can pursue goals independently within defined boundaries. What this means is that we must look at these systems less as greeters and more as teammates. Working independently but with a greater understanding of the process.

Instead of waiting for instructions, agentic AI systems determine how to achieve an outcome, sequence steps across tools and datasets, interpret setbacks, and adjust their approach in real time. They move from language engines to digital collaborators. What is more, they retain memory and context over time.

In life sciences, that difference is profound. Instead of explaining what a clinical trial is, an agentic system could scan electronic health records, identify eligible participants, score candidates, flag anomalies, and escalate only the edge cases that require human judgment. This is the shift from words to workflows.

From a user experience perspective, agentic systems represent a structural way in which work gets done. This is more than an upgrade.

Why Life Sciences Is a Perfect Test Bed

Life science is a data-rich, process-heavy, and tightly regulated environment where autonomous systems must prove they can be trusted. The promises and pressures of agentic AI come into full focus. Here are some ways:

Research and discovery: Agents can automate literature reviews, synthesize findings across massive omics datasets, and surface novel hypotheses in hours instead of weeks.

Clinical trials: They can streamline patient recruitment, continuously monitor safety signals, and reduce the manual data reconciliation that slows progress. We discussed some recruitment tools powered by AI in this post.

Regulatory and compliance workflows: Agentic systems can draft, validate, and cross-check protocol documentation while aligning with GxP standards and FDA requirements, shortening submission timelines without compromising rigor.

Operationally, agents can monitor supply chains, adjust production plans, and flag manufacturing deviations before they cascade into costly delays.

According to McKinsey, 75–85% of pharma workflows and 70–80% of Medtech workflows contain tasks that could be enhanced or automated by agents. At the task level, this translates to 25–40% freed capacity, not by replacing people but by reclaiming fragmented time and reducing friction. 

Industry leaders are now taking the step to act on this for the long term. According to Contract Pharm’s 2026 analysis of AI trends in life science, 94% of science leaders expect AI agents to be essential across their operations. 

What Does This Look Like in Practice

The industry is already moving into action. Earlier this year, NVIDIA and Eli Lilly announced a co-innovation lab backed by up to $1 billion over five years, focused specifically on connecting agentic wet labs with computational dry labs.  Also, at the operational level, IQVIA launched a unified agent platform that has already deployed 150 specialized agents for tasks including clinical trial site selection, a process historically requiring weeks of manual data analysis. For smaller biotech and CRO organizations, the lesson here isn’t about scale, it’s about architecture. 

The Tradeoffs: Power Comes With Friction

While agentic AI delivers real advantages and in regulated environments, well-designed agents can reduce errors and bottlenecks rather than introduce them. The challenges are just as real. The level of autonomy raises several accountability questions. For example, when an agent acts, who owns the decision — the system, the team, or the organization? In addition, security and privacy risks increase when agents have broad access to sensitive data, and some organizations’ readiness often lags behind technical capabilities.

Regulators are already paying attention. Outside of healthcare, financial authorities are scrutinizing agentic systems because autonomous decision-making introduces new governance and stability risks. Keep in mind that the technology works; the operating model is what breaks.

The FDA Is Now Using Agentic AI Itself

In December 2025, the FDA deployed an agency-wide agentic AI platform specifically designed for multi-step workflows, including drug reviews, inspections, surveillance, and compliance tasks. In January 2026, the FDA and EMA jointly released the Guiding Principles of Good AI Practice in Drug Development — ten principles covering human-centric design, risk-based performance assessment, data governance, and lifecycle management across the entire product development lifecycle. 

The Agentic Reality Check: Why So Many Projects Stall

Despite the momentum, adoption remains uneven. Deloitte’s 2026 technology report notes that only about 11% of organizations have agentic systems in production, while 38% are piloting them. Another 42% are still developing a strategy, and 35% have no strategy at all. In another report, Gartner predicts that 40% of agentic AI projects will fail by 2027. A little grim, but this would not be because the tools are inadequate, but because organizations are automating broken processes instead of redesigning them.

Recent studies tracking early agentic deployments in pharma and biotech confirmed this pattern. The organizations with the highest failure rates were those that moved directly from pilot to deployment without redesigning the workflows the agents would inherit. The technology wasn’t the problem; the process architecture was. 

From Conversation to Collaboration

If we are all being honest, AI has always existed on a spectrum. Chatbots occupied one end, being helpful, responsive, but limited. Agentic AI is moving towards another, more goal-driven, adaptive, and operationally embedded. In life sciences, this evolution does not replace scientists, clinicians, or regulatory experts. It bolsters them. It removes repetitive cognitive labor, accelerates insights, and allows human judgment to focus where it matters most.

The future of AI is not about better answers. It is about better action and the systems we trust to carry it out.

Ready to Move From Theory to Trusted Execution?

Agentic AI delivers value only when it is designed around real workflows, regulatory constraints, and organizational readiness. Most failures don’t come from technology — they come from skipping the hard work of process mapping, governance design, and risk alignment.

If your team is exploring agentic AI in life sciences and wants to understand where it makes sense, where it doesn’t, and how to deploy it safely, we can help.

We offer a focused AI Discovery Sprint to:

• Map existing workflows and decision points
• Identify safe, high-impact agentic use cases
• Define governance, guardrails, and success metrics
• Create a clear, regulator-aware implementation roadmap

Whether you’re evaluating your first pilot or trying to move beyond stalled experiments, the goal is clarity — not commitment.

Connect with us to schedule a Discovery Sprint and explore what agentic AI could realistically deliver for your organization.

Like our blog? Subscribe to our newsletter.

Over 4000 marketers love it. Receive information on best marketing practices, exclusive offers, and ways to boost efficiency, quality, and productivity.